The FDA's Pharmacy Compounding Advisory Committee voted on July 23, 2026, to recommend that four unapproved peptides be moved onto a list of substances that licensed compounding pharmacies may legally prepare. The panel backed BPC-157, KPV, TB-500, and MOTS-c by narrow margins, with the closest tally landing at 8-6 and one abstention, according to PharmExec. The recommendation does not carry the force of law, and no pharmacy may compound these substances under the new designation until the FDA completes formal rulemaking.
The vote split along the lines of when panel members were appointed. CBS News reported that more than half a dozen individuals with connections to the peptide industry joined the committee before the two-day session, and all of those members voted in favor of listing BPC-157 for compounding. Among the 24 public speakers who addressed BPC-157 on the first day, four scientists argued the compound should remain restricted.
For pharmacies, prescribers, and patients tracking whether are peptides legal in a given context, the July 23 vote represents a directional shift in federal regulation without an immediate change in enforcement. The peptides remain unapproved drugs. No phase 1 through phase 3 clinical trials have been completed for any of the four compounds under the FDA's new-drug pathway, and the agency has not established standardized dosing, validated indications, or a benefit-risk profile for them. What the vote does is recommend removing these substances from Category 2 of the FDA's bulks list, where they have sat since 2023, and placing them in Category 1, the designation that permits compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Figure 1: Biomedical laboratory assay and analytical documentation.
Category 2 to Category 1: what the reclassification governs
A pharmacist writing in Pharmacy Times described the change in blunt terms: moving a peptide from Category 2 to Category 1 is a regulatory designation governing whether licensed compounding pharmacies may legally prepare it. "That's it. That's the whole change," the author wrote. The reclassification does not mean the FDA has approved these peptides as drugs. FDA drug approval requires a fundamentally different process involving formal clinical trials and a new drug application or biologics license application review, none of which has occurred for BPC-157, KPV, TB-500, or MOTS-c.
The 2023 Category 2 placement had cited concerns including immunogenicity, impurities in available formulations, and limited clinical data. That action effectively barred compounding pharmacies from preparing the peptides and shifted consumer demand toward unregulated online marketplaces selling products labeled "for research use only" and "not for human consumption." Health and Human Services Secretary Robert F. Kennedy Jr. announced a policy direction in February 2026 to reverse the Category 2 designations, and the July PCAC meeting represented the formal advisory step in that process.
The FDA itself did not endorse the panel's recommendation. Agency scientists had recommended against including all seven peptides under review, citing insufficient clinical data and lack of standardized chemical characterization. NPR reported that the FDA is not required to follow advisory committee recommendations, though it typically does.
Rulemaking, not a podcast announcement
The vote is a recommendation transmitted to the broader FDA for a final decision. The agency told the Guardian it was considering the PCAC's recommendations and would make a determination after consulting with the United States Pharmacopeia and reviewing other available information. Formal notice-and-comment rulemaking must follow, a process NPR described as potentially stretching into next year or 2028.
The Pharmacy Times pharmacist cautioned readers against treating a policy announcement or an advisory vote as a rule change. Until the FDA formally updates its bulks list and licensed compounding pharmacies complete raw-material sourcing, batch validation, and sterility testing, the legal status of these peptides in a compounding context has not changed. Operational resumption will lag any announcement.
On the second day of the meeting, July 24, the panel voted to recommend two additional peptides, Epitalon and Semax, for compounding and rejected a third, emideltide. The six favorable recommendations now sit with FDA leadership awaiting the next procedural step.
For consumers and clinicians distinguishing these unapproved compounds from the small number of fda approved peptides such as semaglutide and tirzepatide, the regulatory gap remains wide. The July vote opens a pathway toward legal pharmacy preparation. It does not close the evidence gap that FDA staff flagged, and it does not obligate the agency to finalize the reclassification on any set timeline. The next concrete milestone is the publication of a proposed rule in the Federal Register, which has not yet appeared.
